Home / Publication / An Analysis on Distribution and Inter-relationships of Biomarkers Under Rivaroxaban in Japanese Patients with Non-valvular Atrial Fibrillation (CVI ARO 1)

論文

An Analysis on Distribution and Inter-relationships of Biomarkers Under Rivaroxaban in Japanese Patients with Non-valvular Atrial Fibrillation (CVI ARO 1)

Author(s): Shinya Suzuki, Takeshi Yamashita, Hidefumi Kasai, Takayuki Otsuka, Koichi Sagara

Year: 2018年3月15日

How Model-informed drug development rescue projects from a risky situation

事例紹介

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

論文

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

ウェビナー

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

ウェビナー

Powered by Translations.com GlobalLink Web Software

An Analysis on Distribution and Inter-relationships of Biomarkers Under Rivaroxaban in Japanese Patients with Non-valvular Atrial Fibrillation (CVI ARO 1)

An Analysis on Distribution and Inter-relationships of Biomarkers Under Rivaroxaban in Japanese Patients with Non-valvular Atrial Fibrillation (CVI ARO 1)

How Model-informed drug development rescue projects from a risky situation

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

メルマガ登録

クイックアクセス

ソリューション

お問合せ

An Analysis on Distribution and Inter-relationships of Biomarkers Under Rivaroxaban in Japanese Patients with Non-valvular Atrial Fibrillation (CVI ARO 1)

How Model-informed drug development rescue projects from a risky situation​

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

メルマガ登録

クイックアクセス

ソリューション

お問合せ

How Model-informed drug development rescue projects from a risky situation